Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Verdiva Bio Limited ("Verdiva" or "the Company") today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other ...

For healthcare investors, though, it represented yet another reason to dump some stock. Trump’s appointment of industry ...

"We had three kids in day care at the same time," Almond said, noting the cost can often be a burden for many families.

When looking for a place to grow a life sciences business over the long term, sometimes the biggest location isn't ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY and Novo Nordisk NVO stock. As the major players in the hyper-scale ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressin ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders ... showed up on publicly available options history that we track here at Benzinga.

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...